MarketWatch

Retail investors were doing what they do best on Wednesday: Buying the dip in SpaceX shares aggressively, even as the company’s stock sank after it released its first earnings report.

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

Jeff Dean, Google’s chief scientist and one of its company’s first employees, is leaving to launch his own company.

What a difference a week makes. The S&P 500 has surged more than 6% over the past five days, its biggest gain since last year’s tariff tantrum.

Morgan Stanley expects $64 billion in capital spending from SpaceX this year. The company is dramatically ramping up AI investments.

The largest part of the economy grew in July at a robust pace, but scattered shortages of key supplies and dogged inflation raised the cost of business and companies responded by keeping a lid on hiring.